Selinexor: Phase I data

Data from 11 evaluable pediatric patients with relapsed or refractory AML or mixed phenotype leukemia in a Phase I trial showed that 30, 40, 55 and 70 mg/m 2 oral selinexor on days 1, 3, 8, 10, 22 and...